Fosun Pharma Grants Eisai Exclusive License for Hansizhuang Commercialization

Fosun Pharma announced on February 5 that it has entered into a licensing agreement with Japanese pharmaceutical company Eisai Co., Ltd. According to Jin10, the agreement grants Eisai exclusive rights to commercialize the product Hansizhuang® (serplulimab injection) within specified regions and fields. Eisai will pay Fosun Pharma an upfront fee of $75 million, along with regulatory milestone payments totaling up to $80.01 million, contingent upon achieving various regulatory milestones in the designated regions. Additionally, commercial sales milestone payments could reach up to $233.33 million, based on annual net sales levels of the licensed product in the region. Eisai will also pay royalties calculated as a double-digit percentage of the annual net sales of the licensed product in the region.